In this video, we explore the mechanism of mutagenesis of molnupiravir, an oral antiviral drug that was invented at Emory University, and is being developed by Merck in collaboration with Ridgeback Biotherapeutics.
Molnupiravir is a broad spectrum antiviral that was originally developed for influenza, but right now scientists are focusing on fighting the SARS-CoV-2 virus. Data shows how it reduced the risk of hospitalization or death by approximately 50% compared to placebo for Patients with Mild or Moderate COVID-19.
Merck Plans to Seek Emergency Use Authorization in the U.S. as Soon as Possible and to Submit Applications to Regulatory Agencies Worldwide. If Authorized, Molnupiravir Could be the First Oral Antiviral Medicine for COVID-19.
Kabinger et al. (2021). Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 28, 740–746.
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
Nanome is the leader in collaborative structure-based design through virtual reality. Explore the nanoscale like never before and experience a more intuitive way to interact with small molecules and/or protein structures through the latest in visualization technology. Nanome enables global real-time collaboration and we’re working closely with some of the top pharmaceutical research facilities and academic research institutions.
Nanome is compatible with the HTC Vive and Oculus Rift. Get started today by downloading Nanome for free on:
To learn more visit:
or, follow us on:
Twitter & Insta: @nanome_inc
Be sure to also check out our blockchain platform, Matryx, which will serve as the backend IP tracking mechanism for Nanome. More info at https://www.matryx.ai